Skip to content
Screener

EPS (Diluted) at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
-$0.03-103%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
-$19.55-954%
Pacific Biosciences of California logo
Pacific Biosciences of CaliforniaPACB
-$0.140.0%
iRadimed logo
iRadimedIRMD
$0.45+21.6%
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
$2.15+18.1%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
-$0.19

Other financials

Income statement

See full
Revenue$8.1M+10.9%
Gross profit$1.2M+341%
Operating income-$12.3M-1.4%
Net income-$12.9M-9.0%

Balance sheet

See full
Cash & equivalents$15.0M-19.6%
Total debt$23.5M+318%
Total equity$17.7M-67.5%
Total assets$58.5M-22.7%

Cash flow

See full
Operating cash flow-$12.7M-30.9%
CapEx$394.0K+23.5%
Free cash flow-$12.5M-24.0%

Valuation

See full
Market cap$83.77M-26.0%
Enterprise value$92.33M-7.8%
P/S2.4×-1.4×

Profitability

See full
Gross margin6.4%
Operating margin-141.5%-9.3pp
Net margin-145.6%-0.1pp
FCF margin-114.8%-9.6pp

Returns & leverage

See full
Return on equity-141.6%-501pp
Debt / equity1.3×+1.2×
Current ratio2.5×-1.1×

Where this comes from

Reported directly by Rapid Micro Biosystems in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Rapid Micro Biosystems’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 7:33 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001380106-26-000101
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Interest expense(646)(12)(1,285)(24)
Other expense, net(50)(38)(82)(87)
Total other income (expense), net(556)301(971)706
Loss before income taxes(12,878)(11,847)(27,145)(23,103)
Income tax expense45115318
Net loss$(12,923)$(11,858)$(27,198)$(23,121)
Net loss per share — basic and diluted$(0.27)$(0.27)$(0.58)$(0.52)
Weighted average common shares outstanding — basic and diluted48,346,66344,648,60247,008,32244,321,566

Item 1. Financial Statements

FAQ

What is Rapid Micro Biosystems's EPS (diluted)?
Rapid Micro Biosystems (RPID) reported EPS (diluted) of -$0.27 in Q2 2026.
How has Rapid Micro Biosystems's EPS (diluted) changed year-over-year?
Rapid Micro Biosystems's EPS (diluted) decreased by 0.0% year-over-year, from -$0.27 to -$0.27.
What is the long-term trend for Rapid Micro Biosystems's EPS (diluted)?
Over 3 years (2022 to 2025), Rapid Micro Biosystems's EPS (diluted) has grown at a -9.3% compound annual growth rate (CAGR), from -$1.42 to -$1.06.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Rapid Micro Biosystems's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude